PainChek Ltd (AU:PCK)
ASX:PCK
Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$27.17M
Enterprise ValueAU$24.48M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring SaaS Revenue ModelA subscription/usage-based SaaS model creates recurring, contractable revenue tied to facility and resident counts. That generates scalable, high-visibility revenue as deployments expand, supports predictable customer lifetime value, and aligns incentives for wider clinical adoption over months to years.
Improving Revenue And Gross MarginAccelerating top-line growth and rising gross margin indicate improving unit economics from the software platform. Sustained revenue growth plus margin expansion suggests the business can leverage fixed costs, improving operating leverage and making profitability attainable as scale increases over the medium term.
No Debt On Balance SheetBeing debt-free reduces fixed financial obligations and interest exposure, preserving operational flexibility. That lowers default and covenant risk, making it easier to prioritize product investment or raise equity if needed, which is valuable for a growth-stage digital health business over months to years.
Bears Say
Sustained Heavy Cash BurnPersistent negative operating and free cash flow of roughly -6.8M annually establishes ongoing funding needs. That drains runway, forces recurring capital raises or dilution, and constrains ability to invest in commercialization or regulatory pathways without external financing over the coming 2-6 months.
Deep And Persistent UnprofitabilityExtremely negative net and operating margins mean current revenues are far from covering fixed and operating costs. Without material scale or structural cost reductions, profitability is unlikely in the near term, leaving the business reliant on continued funding and execution to reach breakeven.
Negative Shareholders' EquityNegative equity reflects accumulated losses and a diminished capital buffer, which can impede access to certain financing, affect counterparty confidence, and limit strategic flexibility. Restoring equity will require profitable operations or fresh capital, a meaningful structural hurdle over the medium term.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.13 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$27.17M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 77 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-1009.84%
Trailing 12-Months
Asset Growth
7.04%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---